Journal of Clinical Oncology, Vol 5, 459-463, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Carboplatin and recurrent childhood brain tumors

JC Allen, R Walker, E Luks, M Jennings, S Barfoot and C Tan

Carboplatin, a cisplatin analogue, was administered as an intravenous (IV) one-hour infusion in a 4-consecutive weekly dose schedule to 44 patients with recurrent childhood brain tumors. Twenty-four patients were registered on our phase I, and 20 on our phase II studies. The maximum tolerable dose derived from our phase I study was 210 mg/m2/wk in patients with solid tumors, and the recommended dose for subsequent pediatric phase II studies was 175 mg/m2/wk. This dose was administered to 14 patients in the phase I and all 20 patients in the phase II study. Nine of 36 (25%) evaluable patients in the combined studies experienced objective responses for a median duration of 10+ months. Seven of nine responders had received prior cisplatin. Disease-specific response rates were as follows: medulloblastoma, six of 14 (43%) with three complete (CR) and three partial responses (PR); pineoblastoma, one of one (PR); germinoma, one of two (CR); and brainstem glioma, one of eight (13%) (PR). Carboplatin had mild emetic effects but no significant auditory or renal toxicity. Thrombocytopenia (less than 49,000) was encountered in nine of 28 (32%) evaluable trials at a dose of 175 mg/m2/wk. Because of its low potential for auditory, renal, and emetic toxicity, ease of administration, and high disease-specific activity, carboplatin deserves further study in multiagent phase II and III trials, especially in chemotherapy-sensitive diseases such as medulloblastoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. A. Laurie, J. K. Gray, J. Zhang, M. Leggas, M. Relling, M. Egorin, C. Stewart, and M. A. Dyer Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma Clin. Cancer Res., October 15, 2005; 11(20): 7569 - 7578. [Abstract] [Full Text] [PDF]

				S. Modak, S. Gardner, I. J. Dunkel, C. Balmaceda, M. K. Rosenblum, D. C. Miller, S. Halpern, and J. L. Finlay Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors J. Clin. Oncol., May 15, 2004; 22(10): 1934 - 1943. [Abstract] [Full Text] [PDF]

				R. E. Taylor, C. C. Bailey, K. Robinson, C. L. Weston, D. Ellison, J. Ironside, H. Lucraft, R. Gilbertson, D. M. Tait, D. A. Walker, et al. Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study J. Clin. Oncol., April 15, 2003; 21(8): 1581 - 1591. [Abstract] [Full Text] [PDF]

				R. J. Packer, P. Cogen, G. Vezina, and L. B. Rorke Medulloblastoma: Clinical and biologic aspects Neuro-oncol, July 1, 1999; 1(3): 232 - 250. [Abstract] [PDF]

				D. A Walker, J. A G Punt, and M. Sokal Clinical management of brain stem glioma Arch. Dis. Child., June 1, 1999; 80(6): 558 - 564. [Full Text]

				R. J. Packer and J. L. Finlay Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors Oncologist, December 1, 1996; 1(6): 381 - 393. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain, D. Barba, P. Kormanik, A. M. Berson, W. M. Saunders, and M. C. Shea Concurrent Cisplatin Therapy and Iodine 125 Brachytherapy for Recurrent Malignant Brain Tumors Arch Neurol, February 1, 1995; 52(2): 162 - 167. [Abstract] [PDF]

				C. F. Torres, S. Rebsamen, J. H. Silber, L. N. Sutton, L. T. Bilaniuk, R. A. Zimmerman, J. W. Goldwein, P. C. Phillips, and B. J. Lange Surveillance Scanning of Children with Medulloblastoma N. Engl. J. Med., March 31, 1994; 330(13): 892 - 895. [Abstract] [Full Text]

				B. L. Maria, K. Rehder, T. A. Eskin, L. M. Hamed, E. B. Fennell, R. G. Quisling, J. P. Mickle, R. B. Marcus Jr, W. E. Drane, N. P. Mendenhall, et al. Topical Review Article: Brainstem Glioma: I. Pathology, Clinical Features, and Therapy J Child Neurol, April 1, 1993; 8(2): 112 - 128. [Abstract] [PDF]